Page last updated: 2024-11-07

resiquimod

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S 28463: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159603
CHEMBL ID383322
CHEBI ID36706
SCHEMBL ID34159
MeSH IDM0384842

Synonyms (75)

Synonym
rx8 ,
vml-600
1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol
1-(4-amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol
s-28463
r-848
CHEBI:36706 ,
resiquimod
r 848
1-[4-amino-2-(ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
144875-48-9
r848 compound
s 28463
R848 ,
bdbm50241029
cd-11301
cd11301
CHEMBL383322 ,
1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
1h-imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-
resiquimod [inn]
v3dmu7pvxf ,
unii-v3dmu7pvxf
4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1h-imidazo(4,5-c)quinoline-1-ethanol
1-(4-amino-2-(ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
alpha-dimethyl-1h-imidazo(4,5-c)quinoline-1-ethanol
AKOS016003509
S28463 ,
S8133
gtpl5051
CS-1706
HY-13740
smr002530531
MLS006010212
SCHEMBL34159
resiquimod [mi]
resiquimod [mart.]
4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
resiquimod [who-dd]
resiquimod [usan]
1h-imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-
4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1h-imidazo[4,5-c]quinolin-1-ethanol
4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
resiquimod (r-848)
DTXSID7040603
mfcd00937759
SR-01000944954-1
sr-01000944954
resiquimod, >=98% (hplc)
J-008020
NCGC00370784-05
resiquimod, vml-600, r-848, s-28463
resiquimodr848
'r848; resiquimod'
FT-0763049
1-(4-amino-2-(ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol.
DB06530
r848;s28463
R0197
AS-30885
Q426054
BCP09103
SB17111
HMS3740O09
CCG-267635
EX-A1879
A856222
SY107476
AC-35716
NCGC00370784-01
CS-0645881
HY-13740G
resiquimod (gmp)

Research Excerpts

Overview

Resiquimod (RSQ) is an imidazoquinolinamine derivative and TLR-7/8 agonist. It could enhance the antitumor activity of immune checkpoint blockade when these agents are combined as a treatment for melanoma.

ExcerptReferenceRelevance
"Resiquimod is a Toll-like receptor (TLR)-7 and TLR-8 agonist that, like imiquimod, belongs to the class of imidazoquinolines, small organic molecules with potent antiviral and anticancer activity. "( Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis.
Farr, MA; Joshi, TP; Lewis, DJ, 2021
)
3.51
"Resiquimod (RSQ) is an imidazoquinolinamine derivative and TLR-7/8 agonist that could enhance the antitumor activity of immune checkpoint blockade when these agents are combined as a treatment for melanoma."( Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Geary, SM; Naguib, YW; Salem, AK; Tambunlertchai, S, 2023
)
1.93
"Resiquimod is an immunopotent toll-like receptor 7/8 agonist with antitumor activity. "( Systemic Immunotherapy with Micellar Resiquimod-Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model.
Allen, R; Ferrara, KW; Fite, BZ; Ilovitsh, A; Ingham, ES; Kakwere, H; Kheirolomoom, A; Lewis, JS; Liu, C; Nura-Raie, M; Tam, SM; Tumbale, SK; Wu, B; Zhang, H, 2021
)
2.34
"Resiquimod (R-848) is an immune response modifier activating toll-like receptor 7 and 8. "( In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds.
Haefeli, WE; Theile, D; Wagner, L; Weiss, J, 2021
)
2.3
"Resiquimod is a small (water-soluble) agonist of the endosome-located Toll-like receptors 7 and 8 (TLR7/8)."( Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Christensen, D; Lattmann, E; Pedersen, GK; Perrie, Y; Roces, CB; Wilkinson, A, 2018
)
1.48
"Resiquimod (R848) is an imidazoquinoline compound with potent antiviral activity and functions through the TLR7/TLR8 MyD88-dependent signaling pathway."( Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine.
Bai, XW; Bao, HF; Cao, YM; Chen, YL; Fu, YF; Li, D; Li, PH; Liu, ZX; Lu, ZJ; Sun, P; Xie, BX; Zhou, CX, 2014
)
2.57
"Resiquimod is a compound belonging to the imidazoquinoline family of compounds known to signal through Toll-like receptor 7. "( Modulation of the allergic asthma transcriptome following resiquimod treatment.
Camateros, P; Henri, J; Hudson, TJ; Kanagaratham, C; Radzioch, D; Sladek, R, 2009
)
2.04
"Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions."( Resiquimod, a topical drug for viral skin lesions and skin cancer.
French, LE; Meyer, T; Stockfleth, E; Surber, C, 2013
)
3.28
"Resiquimod is a Toll-like receptor 7 (TLR7) and TLR8 agonist that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines. "( Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
Meng, TC; Sauder, DN; Senta-McMillian, T; Smith, MH; Soria, I, 2003
)
1.97
"Resiquimod is an imiquimod analog proven to activate dendritic cells through TLR-7."( Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.
Boyer, JD; Calarota, SA; Felber, B; Laddy, D; Otero, M; Pavlakis, G; Weiner, DB, 2004
)
2.49

Effects

Resiquimod has been reported to modulate conventional human monocyte-derived DC (moDC) differentiation. The role of TLR7 and TLR8 is unclear.

ExcerptReferenceRelevance
"Resiquimod treatment has been demonstrated to inhibit the development of allergen induced asthma in experimental models."( Modulation of the allergic asthma transcriptome following resiquimod treatment.
Camateros, P; Henri, J; Hudson, TJ; Kanagaratham, C; Radzioch, D; Sladek, R, 2009
)
1.32
"Resiquimod has been reported to modulate conventional human monocyte-derived DC (moDC) differentiation, but the role of TLR7 and TLR8 is unclear."( The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
Bein, G; Hackstein, H; Jurk, M; Knoche, A; Kubin, T; Nockher, A; Poeling, J; Vollmer, J, 2011
)
1.42

Actions

ExcerptReferenceRelevance
"Resiquimod (R848) can generate TGF-β-producing regulatory T cells (Treg)."( Integrin αvβ6 cooperates with resiquimod to restore antigen-specific immune tolerance in airway allergy.
Liu, DB; Liu, ZG; Ma, F; Mo, LH; Ning, Y; Yang, G; Yang, LT; Yang, PC; Zhang, YY, 2021
)
1.63

Treatment

Resiquimod treatment has been demonstrated to inhibit the development of allergen induced asthma in experimental models. Treatment with resquimod, a TLR7/8 agonist, did not improve survival in mice bearing Pros1-secreting tumors but doubled survival for Pros 1-deleted tumors.

ExcerptReferenceRelevance
"Resiquimod-treated MDSCs significantly enhanced the proliferation of T cells that were treated with anti-CD3 and anti-CD28 monoclonal antibodies."( Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Im, SA; Lee, CK; Lee, M; Lee, YR; Park, CS; Song, S, 2014
)
2.57
"Resiquimod treatment has been demonstrated to inhibit the development of allergen induced asthma in experimental models."( Modulation of the allergic asthma transcriptome following resiquimod treatment.
Camateros, P; Henri, J; Hudson, TJ; Kanagaratham, C; Radzioch, D; Sladek, R, 2009
)
1.32
"Resiquimod treatment may offer significant advantages to present antiviral therapies for the control of recurrent genital herpes."( Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.
Bernstein, DI; Harrison, CJ; Miller, RL; Tomai, MA, 2001
)
1.32
"Treatment with resiquimod, a TLR7/8 agonist, did not improve survival in mice bearing Pros1-secreting tumors but doubled survival for Pros1-deleted tumors."( Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.
Caskey, L; Earp, HS; Holtzhausen, A; Hunter, D; Story, C; Ubil, E, 2018
)
0.82

Toxicity

ExcerptReferenceRelevance
"02 mg/kg transiently reduced viral levels but was associated with adverse effects similar to interferon-alpha."( Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
Guyader, D; McHutchison, JG; Meng, TC; Patton, H; Pockros, PJ; Tong, MJ; Wright, T, 2007
)
0.85

Compound-Compound Interactions

ExcerptReferenceRelevance
" We propose a novel clinical grade maturation protocol in which TLR ligands poly(I:C) and R848 are combined with PGE2 to generate DC with both high migratory capacity and IL-12p70 production upon T cell encounter."( Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.
Aarntzen, EH; Adema, GJ; Benitez-Ribas, D; Boullart, AC; de Boer, A; de Vries, IJ; Figdor, CG; Jacobs, JF; Kramer, M; Punt, CJ; Scharenborg, NM; Schreibelt, G; Schuurhuis, DH; van de Rakt, MW; Verdijk, P, 2008
)
0.35
" There has been much recent interest in developing therapeutic approaches to enhance antitumor immune responses using novel immunomodulatory agents in combination with standard of care treatments."( Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Adlard, AL; Dovedi, SJ; Honeychurch, J; Illidge, TM; Melis, MH; Stratford, IJ; Wilkinson, RW, 2013
)
0.39
" In this work, we demonstrate that PTT combined with ICB could not only eliminate primary tumors, but also prevent tumor metastasis to the lungs/liver."( Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Cheng, Y; Li, N; Li, P; Lu, Q; Qi, S; Song, Y; Tan, F; Wang, S; Wang, Y; Yang, L; Yang, S, 2019
)
0.51
" The aim of this study was to evaluate the therapeutic efficiency of immunotherapy with thioridazine and loratadine in combination with resiqumiod (R848), a small-molecule TLR7 agonist, in suppressing CRC growth in a mouse model."( Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Chen, T; Lin, G; Lin, X; Wang, X; Zhang, J, 2020
)
0.56
"Challenges with various TLR ligands (TLRLs)in combination with D-galactosamine (GalN) in rodents may mimic diverse conditions of acute inflammation and organ failure."( Use of TLR9 and TLR7/8 agonists in combination with d-galactosamine in exploring models for distinct severities of systemic inflammation relative to liver injury.
Nishizawa, K; Seki, R, 2020
)
0.56
" Our results demonstrated that anti-PD-1 in combination with RSQ can significantly prolong the survival of melanoma-challenged mice, compared to untreated mice and mice treated with anti-PD-1 alone."( Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Geary, SM; Naguib, YW; Salem, AK; Tambunlertchai, S, 2023
)
1.21

Bioavailability

ExcerptReferenceRelevance
" Our findings reveal that an orally bioavailable TLR-7 ligand that stimulates innate antiviral immune pathways in the intestine restores colonization resistance against a highly antibiotic-resistant bacterial pathogen."( TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.
Abt, MC; Artis, D; Becattini, S; Buffie, CG; Carter, RA; Keith, JW; Leiner, I; Osborne, LC; Pamer, EG; Sušac, B, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, these molecules have high bioavailability that results in unacceptable levels of systemic inflammation due to adjuvant toxicity, thereby greatly limiting their use."( Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators.
Esser-Kahn, AP; Kimani, FW; Manna, S; Moser, B; Nihesh, N; Shen, J, 2021
)
0.62
" However, the poor bioavailability and potential toxicity of this combo strategy remain a challenge."( Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Guo, W; Jia, D; Li, G; Li, J; Liu, R; Lu, X; Lu, Y; Lv, M; Wang, F; Wang, R; Wei, J; Yuan, F; Zhu, W, 2023
)
1.22

Dosage Studied

To investigate the optimal dosing regimens of the Toll-like receptor 7/8 agonist resiquimod in terms of efficacy, safety and tolerability.

ExcerptRelevanceReference
" This clinically validated mouse model will help to investigate whether more potent agonists or optimised dosing schedules, will be successful strategies for targeting TLR7 in patients."( Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.
Bright, H; Burden, F; Colman, P; Corey, T; Fidock, M; Heyen, J; Horscroft, N; Khodai, T; Laxton, C; Mechiche, H; Perkins, H; Rawal, J; Rodrigues, D; Westby, M, 2012
)
0.38
" We show that the synergy resulting from combinatorial stimuli (poly(I:C) and R848 is also regulated by the order and dosage of the TLR agonists."( The synergy in cytokine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages.
Ho, B; Leung, BP; Lin, B; Ling Ding, J; Liu, Q; Suet Ting Tan, R; Tucker-Kellogg, L, 2013
)
0.39
" These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation."( Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Altman, MD; Andresen, B; Baker, J; Brubaker, JD; Chen, H; Chen, Y; Childers, M; Donofrio, A; Ferguson, H; Fischer, C; Fischmann, TO; Gibeau, C; Hicks, A; Jin, S; Kattar, S; Kleinschek, MA; Leccese, E; Lesburg, C; Li, C; Lim, J; Liu, D; Maclean, JKF; Mansoor, F; Moy, LY; Mulrooney, EF; Necheva, AS; Northrup, A; Presland, J; Rakhilina, L; Smith, GF; Torres, L; Yang, R; Zhang-Hoover, J, 2017
)
0.46
"To investigate the optimal dosing regimens of the Toll-like receptor 7/8 agonist resiquimod in terms of efficacy, safety and tolerability."( Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.
Anliker, M; Brüning, H; Dummer, R; French, LE; Hengge, UR; Hofbauer, GFL; Hunger, T; Kenzelmann, R; Popp, G; Reinhold, U; Stockfleth, E; Surber, C; Szeimies, RM; Ulrich, C, 2019
)
1.17
" The dosing regimens that used the biological end point (arms 4/5) proved equally efficacious as predefined treatment durations and may therefore be suitable for personalized AK treatment."( Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.
Anliker, M; Brüning, H; Dummer, R; French, LE; Hengge, UR; Hofbauer, GFL; Hunger, T; Kenzelmann, R; Popp, G; Reinhold, U; Stockfleth, E; Surber, C; Szeimies, RM; Ulrich, C, 2019
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazoquinoline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency37.90830.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)IC50 (µMol)2.05600.05201.20935.6000AID1679179
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Toll-like receptor 8Homo sapiens (human)EC50 (µMol)4.34000.48004.26369.0000AID1068404; AID1313108; AID1504604; AID1646839; AID1666733; AID1814611; AID719614
Toll-like receptor 7Homo sapiens (human)EC50 (µMol)0.85430.00721.57446.8000AID1068405; AID1504602; AID1646838; AID1666732; AID1679178; AID1814610; AID474844; AID719613
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Toll-like receptor 8Homo sapiens (human)ECmax (µMol)10.00000.08005.040010.0000AID1666737
Toll-like receptor 8Homo sapiens (human)MEC0.79330.08001.35173.6500AID1420309; AID1666737; AID1666739
Toll-like receptor 7Homo sapiens (human)ECmax (µMol)10.00000.08005.040010.0000AID1666737
Toll-like receptor 7Homo sapiens (human)MEC0.09000.00300.06570.1000AID1420308; AID1666737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
purine nucleoside catabolic process7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA repair7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to oxidative stress7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
male gonad development7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA protection7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
response to cadmium ion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
regulation of protein phosphorylationToll-like receptor 8Homo sapiens (human)
inflammatory responseToll-like receptor 8Homo sapiens (human)
response to virusToll-like receptor 8Homo sapiens (human)
immunoglobulin mediated immune responseToll-like receptor 8Homo sapiens (human)
negative regulation of interleukin-12 productionToll-like receptor 8Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 8Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 8Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-1 beta productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 8Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 8Homo sapiens (human)
toll-like receptor 8 signaling pathwayToll-like receptor 8Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 8Homo sapiens (human)
innate immune responseToll-like receptor 8Homo sapiens (human)
positive regulation of innate immune responseToll-like receptor 8Homo sapiens (human)
defense response to virusToll-like receptor 8Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 8Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 8Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 8Homo sapiens (human)
regulation of protein phosphorylationToll-like receptor 7Homo sapiens (human)
inflammatory responseToll-like receptor 7Homo sapiens (human)
canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
I-kappaB phosphorylationToll-like receptor 7Homo sapiens (human)
JNK cascadeToll-like receptor 7Homo sapiens (human)
positive regulation of chemokine productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-alpha productionToll-like receptor 7Homo sapiens (human)
positive regulation of interferon-beta productionToll-like receptor 7Homo sapiens (human)
positive regulation of type II interferon productionToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-8 productionToll-like receptor 7Homo sapiens (human)
toll-like receptor 7 signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
innate immune responseToll-like receptor 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIToll-like receptor 7Homo sapiens (human)
positive regulation of inflammatory responseToll-like receptor 7Homo sapiens (human)
defense response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionToll-like receptor 7Homo sapiens (human)
response to cGMPToll-like receptor 7Homo sapiens (human)
cellular response to mechanical stimulusToll-like receptor 7Homo sapiens (human)
cellular response to virusToll-like receptor 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionToll-like receptor 7Homo sapiens (human)
toll-like receptor signaling pathwayToll-like receptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
5'-(N(7)-methylguanosine 5'-triphospho)-[mRNA] hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
protein binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
dATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
snoRNA binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
metal ion binding7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
ATP diphosphatase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
2-hydroxy-dATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
N6-methyl-(d)ATP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
O6-methyl-dGTP hydrolase activity7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
DNA bindingToll-like receptor 8Homo sapiens (human)
RNA bindingToll-like receptor 8Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 8Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 8Homo sapiens (human)
signaling receptor activityToll-like receptor 8Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 8Homo sapiens (human)
double-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
single-stranded RNA bindingToll-like receptor 7Homo sapiens (human)
protein bindingToll-like receptor 7Homo sapiens (human)
siRNA bindingToll-like receptor 7Homo sapiens (human)
pattern recognition receptor activityToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
acrosomal vesicle7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
extracellular space7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nucleus7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrion7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
mitochondrial matrix7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytosol7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
nuclear membrane7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
cytoplasm7,8-dihydro-8-oxoguanine triphosphataseHomo sapiens (human)
Golgi membraneToll-like receptor 8Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 8Homo sapiens (human)
external side of plasma membraneToll-like receptor 8Homo sapiens (human)
endosome membraneToll-like receptor 8Homo sapiens (human)
endolysosome membraneToll-like receptor 8Homo sapiens (human)
plasma membraneToll-like receptor 8Homo sapiens (human)
Golgi membraneToll-like receptor 7Homo sapiens (human)
cytoplasmToll-like receptor 7Homo sapiens (human)
lysosomeToll-like receptor 7Homo sapiens (human)
endosomeToll-like receptor 7Homo sapiens (human)
endoplasmic reticulumToll-like receptor 7Homo sapiens (human)
endoplasmic reticulum membraneToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
endosome membraneToll-like receptor 7Homo sapiens (human)
early phagosomeToll-like receptor 7Homo sapiens (human)
endolysosome membraneToll-like receptor 7Homo sapiens (human)
receptor complexToll-like receptor 7Homo sapiens (human)
plasma membraneToll-like receptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (141)

Assay IDTitleYearJournalArticle
AID1814657Antitumor immunity against mouse CT26 cells implanted in BALB/c mouse assessed as increase in infiltration of CD8+ T cytotoxic lymphocytes at 25 ug, ip administered once a week for 23 days by flow cytometry analysis
AID1420308Agonist activity at human TLR7 expressed in HEK293 cells after 6 hrs by NFkappaB-luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
AID1814637Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of VEGF secretion incubated for 12 hrs by multiplexed immunoassay
AID1666740Agonist activity at TLR8 in human PBMC assessed as TNFalpha level at 10 uM2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID1766367Systemic toxicity in CT26 cells xenografted BALB/c mouse tumor model assessed as reduction in white blood count in peripheral blood at 20 nmol, IT and measured after 24 hrs by hematological analysis2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators.
AID1646849Agonist activity at TLR7/8 in dog PBMC assessed as maximal increase in TNFalpha secretion at 20 uM after 30 to 48 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1068405Agonist activity at human TLR-7 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID1666738Agonist activity at TLR7 in human PBMC assessed as IFNalpha stimulation at 10 uM2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID1814684Acute toxicity in BALB/c mouse assessed as decrease in locomotor activity at 15 to 80 mg/kg, ip administered as single dose measured after 24 hrs
AID1814670Acute toxicity in BALB/c mouse assessed as decrease in locomotor activity at 15 to 80 mg/kg, ip administered as single dose
AID1814665Acute toxicity in BALB/c mouse assessed as mortality at 120 mg/kg, ip administered as single dose
AID1814659Antitumor immunity against mouse CT26 cells implanted in BALB/c mouse assessed as increase in infiltration of CD8+ T cytotoxic lymphocytes at 25 ug, ip administered once a week with anti-PD-1 antibody for 23 days by flow cytometry analysis
AID261882Emetic activities in ferret at 3 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1814686Acute toxicity in BALB/c mouse assessed as white discharge from eyes at 15 to 80 mg/kg, ip administered as single dose measured after 24 hrs
AID1814683Acute toxicity in BALB/c mouse assessed as body weight regain at 60 mg/kg, ip administered as single dose measured after 3 days
AID1814635Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of IL-12p40 production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID341171Increase in 2',5'-oligoadenylate synthase level in human PBMC after 24 hrs by PCR method relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID474844Agonist activity at human TLR7 expressed in HEK293 cells coexpressing pNiFty2-SEAP reporter by reporter gene assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID261879Induction of IFN in cynomolgus monkey at 0.3 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID341166Increase in 2',5'-oligoadenylate synthase level in human PBMC after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1814642Antitumor activity against mouse CT26 cells implanted in BALB/c mouse assessed as reduction in tumor volume at 25 ug, ip administered once a week in presence of anti-PD-1 antibodies and measured every 3 days for 23 days
AID1666732Agonist activity at human TLR7 expressed in HEK293 cells assessed as induction of NFKappaB activity after 24 hrs by SEAP reporter gene assay2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID1666741Agonist activity at TLR8 in human PBMC assessed as induction of myeloid dendritic cell maturation by measuring increase in CD86 level at 0.1 uM after 6 hrs by flow cytometry relative to control2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID1814611Agonist activity at human TLR8 expressed in HEK293 cells incubated for 6 to 16 hrs by SEAP reporter gene assay
AID261873Induction of IFN in C3H/HeJ mouse splenocytes at 30 nM2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1068399Agonist activity at TLR7/TLR8 in human PBMC assessed as induction of TNF-alpha production at 22.5 uM after 24 hrs by flow cytometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID1814671Subacute toxicity in BALB/c mouse assessed as body weight loss at 1.12 g, ip administered as single dose
AID341162Antiviral activity against HCV infected human Huh7 replicon cells treated for 48 hrs with drug-induced single donor human PBMC supernatants assessed as viral levels by luciferase assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1646844Agonist activity at TLR7/8 in dog PBMC assessed as IL-2 secretion at 20 uM after 29 hrs by ELISA (Rvb = 47 +/- 20 pg/ml)2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID719613Agonist activity at human TLR7 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
AID1814649Toxicity in BALB/c mouse implanted with mouse CT26 cells assessed as decrease in body weight at 25 ug, ip administered once a week in presence of anti-PD-1 antibodies for 23 days
AID1814667Acute toxicity in BALB/c mouse assessed as white discharge from eyes at 15 to 80 mg/kg, ip administered as single dose
AID341163Antiviral activity against HCV infected human Huh7 replicon cells treated for 48 hrs with drug-induced mixed donor human PBMC supernatants assessed as viral levels by luciferase assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1814669Acute toxicity in BALB/c mouse assessed as maximum tolerated dose
AID1814634Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of IP-10 production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1068401Agonist activity at TLR7/TLR8 in C57BL/6 mouse BMDC assessed as induction of IL-12p40 production at 30 uM after 3 days by flow cytometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID1646853Agonist activity at TLR7/8 in dog PBMC assessed as increase in IL-12 secretion at 20 uM measured over 24 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID341160Induction of IFNalpha2a level in human PBMC assessed as drug level causing maximal cytokine induction after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1814627Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of TNFalpha production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1068400Agonist activity at TLR7/TLR8 in C57BL/6 mouse BMDC assessed as induction of IL-10 production at 30 uM after 3 days by flow cytometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID719610Immunomodulatory activity in C57BL/6 mouse BMDC assessed as IL-1beta production at 30 uM after 3 days by FACS flow cytometric analysis (Rvb = 26.2 +/- 3.7 pg/mL)2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
AID1504604Agonist activity at human TLR8 expressed in HEK cells after 8 to 12 hrs by NFkappaB/SEAP reporter gene assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
AID1313115Agonist activity at TLR7 in human PBMC assessed as IL-6 level in supernatant after 18 hrs2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
AID261885Cmax in ferret at 3 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1646841Agonist activity at TLR7/8 in dog PBMC assessed as IL-12 secretion at 20 uM after 29 hrs by ELISA (Rvb = 18 +/- 8 pg/ml)2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1068402Agonist activity at TLR7/TLR8 in C57BL/6 mouse BMDC assessed as induction of IL-1beta production at 30 uM after 3 days by flow cytometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID341170Antiviral activity against HCV infected human Huh7 replicon cells assessed as viral levels by luciferase assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1814668Acute toxicity in BALB/c mouse assessed as mild diarrhea at 15 to 80 mg/kg, ip administered as single dose
AID1646840Agonist activity at TLR7/8 in dog PBMC assessed as TNFalpha secretion at 20 uM after 29 hrs by ELISA (Rvb = 8 +/- 2 pg/ml)2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1646845Agonist activity at TLR7/8 in dog PBMC assessed as IFNgamma secretion at 20 uM after 29 hrs by ELISA (Rvb = 0.4 +/- 0.7 pg/ml)2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID349532Induction of TLR7 receptor-mediated C57BL/6 mouse BMD cells activation assessed as IL12 production at 5 uM after 24 hrs by ELISA2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
AID1646839Agonist activity at human TLR8 expressed in HEK-Blue cells assessed as induction of NFkappaB activation by measuring increase in SEAP level by SEAP reporter gene-based UV-vis absorbance method2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1814680Antitumor immunity against mouse CT26 cells implanted in BALB/c mouse assessed as increase in Teff/Treg ratio at 25 ug, ip administered once a week for 23 days by flow cytometry analysis
AID1313114Agonist activity at TLR7 in Balb/c mouse splenocytes assessed as IL-6 level in supernatant after 18 hrs2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
AID261880Induction of IFN in cynomolgus monkey at 1 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1504602Agonist activity at human TLR7 expressed in HEK cells after 8 to 12 hrs by NFkappaB/SEAP reporter gene assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
AID349530Induction of TLR7 receptor-mediated C57BL/6 mouse BMD cells activation assessed as upregulation of MHC class-2 at 1 uM after 48 hrs by flow cytometry2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
AID1814674Subacute toxicity in BALB/c mouse assessed as splenomegaly at 15 mg/kg, ip administered as single dose
AID1814685Acute toxicity in BALB/c mouse assessed as mild diarrhea at 15 to 80 mg/kg, ip administered as single dose measured after 24 hrs
AID349529Induction of TLR7 receptor-mediated C57BL/6 mouse BMD cells activation assessed as upregulation of CD86 at 1 uM after 48 hrs by flow cytometry2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
AID475029Induction of IFN secretion in Brown Norway rat plasma at 0.1 mg/kg, intratracheally measured after 2 to 24 hrs by CPE reduction assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID1666739Agonist activity at TLR8 in human PBMC assessed as TNFalpha level2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID719612Immunomodulatory activity in C57BL/6 mouse BMDC assessed as IL-10 production at 30 uM after 3 days by FACS flow cytometric analysis (Rvb = 16.2 +/- 4.7 pg/mL)2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
AID261881Emetic activities in ferret at 0.3 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1814648Toxicity in BALB/c mouse implanted with mouse CT26 cells assessed as decrease in body weight at 25 ug, ip administered once a week for 23 days
AID349531Induction of TLR7 receptor-mediated C57BL/6 mouse BMD cells activation assessed as upregulation of CD40 at 1 uM after 48 hrs by flow cytometry2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation.
AID1814628Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of IL-1beta production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1814678Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of G-CSF production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1646838Agonist activity at human TLR7 expressed in HEK-Blue cells assessed as induction of NFkappaB activation by measuring increase in SEAP level by SEAP reporter gene-based UV-vis absorbance method2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1814681Antitumor immunity against mouse CT26 cells implanted in BALB/c mouse assessed as increase in Teff/Treg ratio at 25 ug, ip administered once a week with anti-PD-1 antibody for 23 days by flow cytometry analysis
AID474845Half life in human plasma by LS-MS analysis2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID261877Induction of IFN in C3H/HeJ mouse splenocytes at 1 nM2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1666737Agonist activity at TLR7/TLR8 in human PBMC assessed as IFN alpha level2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID261871Induction of IFN in C3H/HeJ mouse splenocytes at 3 nM2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID341167Toxicity assessed as increase in IL6 level in human PBMC after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID719609Immunomodulatory activity in C57BL/6 mouse BMDC assessed as TNFalpha production at 30 uM after 3 days by FACS flow cytometric analysis (Rvb = 91.3 +/- 34.5 pg/mL)2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
AID1814640Antitumor activity against mouse CT26 cells implanted in BALB/c mouse assessed as tumor growth delay at 25 ug, ip administered once per week and measured every 3 days for 23 days
AID261878Induction of IFN in cynomolgus monkey at 0.1 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1814610Agonist activity at human TLR7 expressed in HEK293 cells incubated for 6 to 16 hrs by SEAP reporter gene assay
AID1646850Agonist activity at TLR7/8 in dog PBMC assessed as maximal increase in IL-12 secretion at 20 uM after 30 to 48 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID261876Induction of IFN in BALB/c mice at 0.3 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1646852Agonist activity at TLR7/8 in dog PBMC assessed as increase in TNFalpha secretion at 20 uM measured over 24 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID341164Toxicity assessed as increase in TNFalpha level in human PBMC after 6 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID341165Increase in IFNalpha level in human PBMC after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1814629Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of IL-6 production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1814658Antitumor immunity against mouse CT26 cells implanted in BALB/c mouse assessed as increase in infiltration of CD4+ TH1 cells at 25 ug, ip administered once a week with anti-PD-1 antibody for 23 days by flow cytometry analysis
AID1679179Inhibition of MTH1 (unknown origin) using 8-oxo-dGTP as substrate preincubated for 15 mins followed by substrate addition and measured after 20 mins by PPiLight detection reagent based luminescence assay2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
AID1646851Agonist activity at TLR7/8 in dog PBMC assessed as maximal increase in IFN-gamma secretion at 20 uM after 30 to 48 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1814633Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of MIP-1alpha production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1646843Agonist activity at TLR7/8 in dog PBMC assessed as IL-10 secretion at 20 uM after 29 hrs by ELISA (Rvb = 33 +/- 16 pg/ml)2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID474850Induction of type 1 IFN secretion in human PBMC at 30 nM after 18 hrs by ELISA2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID1814666Acute toxicity in BALB/c mouse assessed as body weight loss at 60 mg/kg, ip administered as single dose relative to control
AID475031Selectivity ratio of antiinflammatory activity in ovalbumin and albuminium hydroxide adjuvant-sensitized Brown Norway rat to induction of IFN secretion in Brown Norway rat plasma2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID1814677Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of MCP-1 production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1068403Agonist activity at TLR7/TLR8 in C57BL/6 mouse BMDC assessed as induction of TNF-alpha production at 30 uM after 3 days by flow cytometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID719614Agonist activity at human TLR8 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
AID474851Induction of type 1 IFN secretion in human PBMC at 100 nM after 18 hrs by ELISA2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID1679178Agonist activity at TLR7 in human PBMC assessed as induction of IN-12 stimulation2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
AID341161Toxic induction of IL6 level in human PBMC assessed as drug level causing maximal cytokine induction after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID341173Antiviral activity against HCV infected human Huh7 replicon cells treated with 100 nM drug-induced human PBMC supernatants assessed as viral levels in presence of type I IFN receptor antibody by luciferase assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID341177Toxic induction of TNFalpha level in human PBMC assessed as drug level causing maximal cytokine induction after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID261875Induction of IFN in BALB/c mice at 0.1 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID474852Induction of type 1 IFN secretion in human PBMC at 300 nM after 18 hrs by ELISA2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID1666723Agonist activity at TLR8 in human PBMC assessed as induction of myeloid dendritic cell maturation by measuring increase in MHC-1 level at 0.1 uM after 6 hrs by flow cytometry relative to control2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID341159Toxic induction of IL1-beta level in human PBMC assessed as drug level causing maximal cytokine induction after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID261884Cmax in ferret at 0.3 mg/kg, po2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1766372Systemic toxicity in CT26 cells xenografted BALB/c mouse tumor model assessed as reduction in lymphocyte count in peripheral blood at 20 nmol, IT and measured after 24 hrs by hematological analysis2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators.
AID1814656Antitumor immunity against mouse CT26 cells implanted in BALB/c mouse assessed as increase in infiltration of CD4+ TH1 cells at 25 ug, ip administered once a week for 23 days by flow cytometry analysis
AID1766366Systemic toxicity in CT26 cells xenografted BALB/c mouse tumor model assessed as increase in serum IL-6 level at 20 nmol, IT and measured after 2 hrs2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators.
AID474853Induction of type 1 IFN secretion in human PBMC at 1000 nM after 18 hrs by ELISA2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID261874Induction of IFN in C3H/HeJ mouse splenocytes at 100 nM2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1442704Immunomodulatory activity in human PBMC assessed as induction of IL-6 secretion at 16 uM after 24 hrs by ELISA2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
1-ethyl-3-(6-methylphenanthridine-8-il) urea modulates TLR3/9 activation and induces selective pro-inflammatory cytokine expression in vitro.
AID1068404Agonist activity at human TLR-8 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
AID1420309Agonist activity at human TLR8 expressed in HEK293 cells after 6 hrs by NFkappaB-luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
AID1666733Agonist activity at human TLR8 expressed in HEK293 cells assessed as induction of NFKappaB activity after 24 hrs by SEAP reporter gene assay2020Bioorganic & medicinal chemistry letters, 03-15, Volume: 30, Issue:6
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
AID719611Immunomodulatory activity in C57BL/6 mouse BMDC assessed as IL-12p40 production at 30 uM after 3 days by FACS flow cytometric analysis (Rvb = 260.6 +/- 11.9 pg/mL)2012ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
AID475030Induction of IFN secretion in Brown Norway rat plasma at up to 10 mg/kg, intratracheally measured after 2 to 24 hrs by CPE reduction assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID341168Antiviral activity against HCV infected human Huh7 replicon cells treated for 24 hrs with drug-induced human PBMC supernatants assessed as viral levels by luciferase assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1646854Agonist activity at TLR7/8 in dog PBMC assessed as increase in IFN-gamma secretion at 20 uM measured over 24 hrs by ELISA2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID474856Antiinflammatory activity in ovalbumin and albuminium hydroxide adjuvant-sensitized Brown Norway rat assessed as inhibition of allergen-induced eosinophils influx at 1 mg/kg, intratracheally administered 2 hrs before allergen challenge measured after 24 h2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID261872Induction of IFN in C3H/HeJ mouse splenocytes at 10 nM2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers.
AID1313108Agonist activity at human TLR8 expressed in HEK293 cells incubated for 6 hrs by luciferase reporter gene assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
AID341169Antiviral activity against HCV infected human Huh7 replicon cells treated with drug-induced human PBMC supernatants assessed as viral levels by luciferase assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID474849Induction of type 1 IFN secretion in human PBMC at 10 nM after 18 hrs by ELISA2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
AID1646842Agonist activity at TLR7/8 in dog PBMC assessed as IL-6 secretion at 20 uM after 29 hrs by ELISA (Rvb = 310 +/- 90 pg/ml)2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1814630Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of IL-8 production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1646855Solubility of the compound at >100 uM2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
AID1766365Systemic toxicity in CT26 cells xenografted BALB/c mouse tumor model assessed as increase in serum TNF-alpha level at 20 nmol, IT and measured after 2 hrs2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators.
AID1814632Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of INF-gamma production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID341172Increase in IFNalpha level in human PBMC after 24 hrs relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
AID1814631Agonist activity at human TLR7/8 expressed in human PBMC cells assessed as induction of IL-10 production by measuring concentration required to induce maximal response incubated for 12 hrs by multiplexed immunoassay
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345471Human TLR7 (Toll-like receptor family)2002Nature immunology, Feb, Volume: 3, Issue:2
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
AID1345471Human TLR7 (Toll-like receptor family)2002Nature immunology, Jun, Volume: 3, Issue:6
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (460)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (1.74)18.2507
2000's117 (25.43)29.6817
2010's265 (57.61)24.3611
2020's70 (15.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.41 (24.57)
Research Supply Index6.17 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index64.21 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (3.01%)5.53%
Reviews15 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.22%)0.25%
Other435 (93.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]